Else Nutrition Announces Major Breakthrough as President Trump Signs Pivotal FDA Funding Package That Includes Congressional Directive Streamlining Regulatory Pathway for Non‑Dairy, Non‑Soy Plant‑Based Infant Formula

VANCOUVER, BC – Else Nutrition Holdings Inc. (TSX: BABY; OTCQX: BABYF) today revealed a significant milestone: U.S. President Donald Trump has signed into law the Fiscal Year 2026 federal budget, ending the government shutdown and including a vital directive mandating the Food & Drug Administration (FDA) to streamline regulatory pathways for plant‑based infant formulas that are both non‑dairy and non‑soy. The new law incorporates a report language provision (H. Rept. 119‑172) inserted after intense government affairs work by Else Nutrition, which recognizes that many families seek infant‑nutrition alternatives due to allergies, dietary preferences, or ethical considerations. With the directive now official, Else says it’s positioned to begin direct engagement with the FDA to launch its whole‑food, plant‑based infant‑formula solutions combining almonds, buckwheat and tapioca — leveraging its existing toddler‑nutrition line for the U.S. market. “Congress has sent a clear directive: U.S. regulatory policy will soon catch up to the reality that babies’ nutritional needs and families’ values are evolving,” said co‑founder & CEO Hamutal Yitzhak. “For too many parents, the absence of truly inclusive formula options has been a daily worry.” Else notes that the end of the shutdown allows FDA employees to return to full operations — paving the way for faster regulatory engagement and, ultimately, the arrival of plant‑based infant‑formula choices in the U.S. market. In sum: What was once a regulatory barrier is now a legislative green light — and families seeking non‑dairy, non‑soy infant nutrition may have far more options ahead. #plantbasedinfantformula #nutritioninnovation #ElseNutrition #FDAregulation #SlimScan #GrowthStocks #CANSLIM